Kengo Onochi
Kengo Onochi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Katsunori Iijima
Department of Gastroenterology Akita University Graduate School of Medicine Akita Japan
2 shared publications - Noboru Watanabe
Department of Gastroenterology and Hepatology, Akita University Graduate School of Medicine
2 shared publications - Shigeto Koizumi
Department of Gastroenterology and Hepatology, Akita University Graduate School of Medicine
2 shared publications - Sho Fukuda
Department of Mechanical Engineering, Faculty of Science and Engineering, Kyushu Sangyo University, Fukuoka, Japan
2 shared publications - Tamotsu Matsuhashi
Department of Gastroenterology and Neurology, Akita University Graduate School of Medicine, Akita, Japan
2 shared publications - Yosuke Shimodaira
Department of Gastroenterology Akita University Graduate School of Medicine Akita Japan
2 shared publications
Latest Publications
- Open Access
- 1 January 2022
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 257 (4) , 301-308
Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 January 2022
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 257 (4) , 301-308
Open AccessLeucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 30 April 2021
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 19 (2) , 225-231
Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan
Background/Aims: 5-Aminosalicylic acid (5-ASA) is a basic drug for inducing and maintaining remission for ulcerative colitis. One of its formulations has a coating with a pH-dependent degradation that ensures the release 5-ASA at the terminal ileum. No evidence has been shown concerning the effects of proton pump inhibitors (PPIs) or H2 receptor antagonists (H2RAs) on the clinical course of ulcerative colitis patients in remission. The present study assessed the effect of PPIs or H2RAs on the relapse of ulcerative colitis patients in clinical remission maintained by pH-dependent released 5-ASA.Methods: Ulcerative colitis patients who had been prescribed time- or pH-dependent-released 5-ASA between January 2015 and December 2018 were enrolled in this multicenter retrospective study. The period of remission until relapse occurred was analyzed among the patients taking time-dependent-released 5-ASA or pH-dependent-released 5-ASA with/without PPIs or H2RAs.Results: One hundred and nineteen patients were analyzed in this study. In the primary endpoint, the relapse rate was higher in patients taking pH-dependent-released 5-ASA and PPIs or H2RAs than in those taking the pH-dependent-released 5-ASA without PPIs or H2RAs, while the relapse rate was similar in patients taking the time-dependent-released 5-ASA with or without PPIs or H2RAs concomitantly. Patients with a short duration of disease and middle-aged patients more frequently showed relapse with PPIs or H2RAs than the other patients.Conclusions: The coadministration of PPIs or H2RAs affects the clinical course of ulcerative colitis in remission maintained by pH-dependent-released 5-ASA.
- 30 April 2021
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 19 (2) , 225-231
Open AccessEffect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan
Background/Aims: 5-Aminosalicylic acid (5-ASA) is a basic drug for inducing and maintaining remission for ulcerative colitis. One of its formulations has a coating with a pH-dependent degradation that ensures the release 5-ASA at the terminal ileum. No evidence has been shown concerning the effects of proton pump inhibitors (PPIs) or H2 receptor antagonists (H2RAs) on the clinical course of ulcerative colitis patients in remission. The present study assessed the effect of PPIs or H2RAs on the relapse of ulcerative colitis patients in clinical remission maintained by pH-dependent released 5-ASA.Methods: Ulcerative colitis patients who had been prescribed time- or pH-dependent-released 5-ASA between January 2015 and December 2018 were enrolled in this multicenter retrospective study. The period of remission until relapse occurred was analyzed among the patients taking time-dependent-released 5-ASA or pH-dependent-released 5-ASA with/without PPIs or H2RAs.Results: One hundred and nineteen patients were analyzed in this study. In the primary endpoint, the relapse rate was higher in patients taking pH-dependent-released 5-ASA and PPIs or H2RAs than in those taking the pH-dependent-released 5-ASA without PPIs or H2RAs, while the relapse rate was similar in patients taking the time-dependent-released 5-ASA with or without PPIs or H2RAs concomitantly. Patients with a short duration of disease and middle-aged patients more frequently showed relapse with PPIs or H2RAs than the other patients.Conclusions: The coadministration of PPIs or H2RAs affects the clinical course of ulcerative colitis in remission maintained by pH-dependent-released 5-ASA.
- 25 December 2007
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 42 (12) , 957-961
Clinicopathological study on the intraductal spread of small pancreatic cancer
The aim of this study was to evaluate histopathologically the frequency, direction, and length of intraductal spread (IS) along the main pancreatic duct from the main tumor of small pancreatic cancer.
- 25 December 2007
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 42 (12) , 957-961
Clinicopathological study on the intraductal spread of small pancreatic cancer
The aim of this study was to evaluate histopathologically the frequency, direction, and length of intraductal spread (IS) along the main pancreatic duct from the main tumor of small pancreatic cancer.